the only they can acquire, considering their current cash and cashflow(or lack there of) is a cap raisingmore dilution and another kick in the u know what for shareholderswouldnt mind being wrong tho
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%